EGON-ZEHNDER
7.3.2024 09:31:29 CET | Business Wire | Press release
Egon Zehnder, the world’s preeminent leadership advisory firm, today announced the results of a study that surveyed 581 CFOs worldwide to capture how the role of the chief financial officer has shifted over the past five years. The findings demonstrate a major evolution that has “Super CFOs” tackling new challenges, addressing new priorities, and aspiring even more for the CEO role.
Of the nearly 600 CFOs studied, 82% reported that their role has grown significantly, with the vast majority of CFOs citing how new complexities across environmental, social, and governance matters, mergers and acquisitions, and corporate strategy are driving sweeping change - and opportunity - within their role.
“Our study reveals a momentous evolution with ‘Super CFOs’ not just reacting to the changing business environment, but in fact driving it,” said Arun Dhingra, Global Head of Egon Zehnder’s CFO & Audit Chair Practice. “Through my work, I’ve witnessed this transformative era firsthand, and our CFO study reaffirms the reality that the complexities of the CFO role have propelled these leaders to the forefront of their organizations due to the profound shift in their priorities and substantial growth in their role.”
Guiding the Business: 82% of CFOs report they have taken on new responsibilities that were not part of their remit just five years ago
As business dynamics have changed over the past five years, so too has the nature of the CFO’s workload. When asked what new responsibilities have been added to their plate, CFOs ranked ESG, M&A, and corporate strategy as the top three – signaling not only a reaction to shifting industry and market priorities but new reliance upon CFOs as strategic partners to the CEO and the board. This drastic increase in scope is inspiring CFOs to consider their roster of priorities and what could be excluded from their remit in favor of more pressing tasks. As their mandates expand, nearly half (47%) of CFOs report needing to allocate more time to business strategy to meet the new expectations demanded from them.
Looking to the future, the trend of increased responsibilities is expected to continue. When asked about the competencies that will matter most over the next five years, CFOs ranked driving change, shaping strategy, and developing talent as the most important. In particular, female CFOs were adamant about driving change—57% named this the key competency compared to 40% of male CFOs.
Leading their People: Over 40% of CFOs say it is harder to attract top financial talent today compared to two years ago
While CFOs would like to allocate additional time to strategy and talent development, CFOs view finding talent and IT as least central to the future remit of the role. Two-fifths of CFOs agree that it’s harder to attract top financial talent today than it was two years ago.
Over half of CFOs surveyed are ensuring they’re building and developing the right bench by employing the following strategies – more open and honest feedback to the team, rotating top talent throughout various financial roles, and targeted development programs. CFOs largely agree the top two team members they rely on the most are the Head of FP&A and the Controller/CAO. For finance professionals aspiring to become a CFO, when reflecting on their first CFO role, respondents identified board interaction, external credibility with investors, and co-leadership of the organization with the CEO as key areas that required the most growth.
Managing their Careers: 62% of CFOs want to be chief executives at some point in their career, with 7 in 10 reporting they feel prepared to take on the role now
CFO sentiments are also shifting and expanding when it comes to personal career aspirations. While an expanded, more multifunctional CFO role may help them seize those new opportunities – nearly half say networking and visibility is a major barrier to becoming CEO. What’s more, 44% of CFOs are being approached more often for opportunities, a sign that the significant level of CFO departures seen in 2023 is not slowing down. Among CFOs who reported being approached the most, recruitment outreach is especially strong for female CFOs – women reported being reached out to more often (17%) when compared to men (12%), a sign that organizations are continuing to prioritize gender diversity within the C-Suite.
With growing competition for CFO talent, 60% of respondents say they value a high-quality executive team as well as growth prospects (for 45% of respondents) when considering whether to pursue a new opportunity. The focus on whom they’ll work with, over company valuation and revenue, signals that companies that are more intentional about executive development are better positioned to attract top talent than those that aren’t.
“Maintaining the role of corporate ‘Superhero’ is no easy feat,” said James Stark, lead author of the Super CFO Survey and consultant in the CFO & Audit Chair Practice at Egon Zehnder. “As signs point to the CFO role continuing to grow in complexity, financial leaders will need to keep growing their leadership skills to drive success in their current role – and to help them reach the next step in their career trajectory. From talent development to leading their organization's ESG initiatives, the role of the CFO today is a central figure in charting sustainable growth and ensuring organizational resilience in any industry.”
For more information on Egon Zehnder’s services and the study cited in this press release, please visit www.egonzehnder.com/the-super-cfo.
About Egon Zehnder
Egon Zehnder is the world’s preeminent leadership advisory firm, inspiring leaders to navigate complex questions with human answers. Our 600 consultants across 64 offices and 36 countries are former industry and functional leaders who collaborate seamlessly to deliver the full power of the Firm to every client, every time. We believe that together we can transform people, organizations and the world through leadership. For more information, visit www.egonzehnder.com and follow us on LinkedIn and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306711015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
